Compare EXPO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | RCUS |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1996 | 2018 |
| Metric | EXPO | RCUS |
|---|---|---|
| Price | $53.69 | $23.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $88.00 | $31.90 |
| AVG Volume (30 Days) | 433.8K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $582,014,000.00 | $247,000,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $8.50 | $45.62 |
| P/E Ratio | $91.24 | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $51.91 | $7.92 |
| 52 Week High | $81.95 | $28.72 |
| Indicator | EXPO | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 17.88 | 46.31 |
| Support Level | N/A | $20.20 |
| Resistance Level | $69.96 | $24.33 |
| Average True Range (ATR) | 2.43 | 1.21 |
| MACD | -1.29 | -0.24 |
| Stochastic Oscillator | 10.95 | 4.24 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.